Vipin Chandra: L-Leucine in Controlled Ovarian Hyperstimulation
Vipin Chandra, Director of Matcare Maternity, shared a post on LinkedIn:
“L-Leucine in Controlled Ovarian Hyperstimulation (COH):
A Metabolic Adjuvant Worth Serious Clinical Attention
Poor ovarian response remains one of the most frustrating challenges in ART. Despite protocol refinement and gonadotropin escalation, outcomes often plateau—especially in women with diminished ovarian reserve (DOR) and hypo-responsive follicles.
Increasingly, attention is shifting upstream—from hormones alone to the intracellular metabolic pathways that govern follicular competence.
One nutrient drawing justified mechanistic interest is L-Leucine.
Why L-Leucine Matters Biologically
L-Leucine is a branched-chain amino acid and the most potent physiological activator of the mTOR pathway, a central regulator of:
- granulosa cell proliferation
- protein synthesis
- mitochondrial function
- steroidogenesis
- follicular growth and survival
mTOR signaling is now well established as essential for follicular activation and oocyte competence.
Adhikari et al., PNAS 2010
Mechanistic Advantage in Low-Reserve Ovaries
Unlike insulin-dependent activators, L-Leucine directly activates mTORC1 via Rag-GTPase signaling, supporting cellular metabolism even under stress conditions—precisely the environment seen in aging or hypo-responsive ovaries.
Wolfson et al., Science 2016
Granulosa cells are highly amino-acid sensitive, and preclinical work shows leucine improves:
- mitochondrial activity
- steroidogenic capacity
- granulosa cell survival
Zhang et al., Biology of Reproduction 2017
What Clinical Data Suggest So Far
While IVF-specific RCTs isolating L-Leucine are limited, human nutritional and metabolic studies consistently suggest that optimizing amino-acid–mTOR signaling improves ovarian responsiveness.
L-Leucine has also been studied as part of multi-nutrient metabolic strategies, commonly combined with:
- myo-inositol (FSH/insulin signaling, oxidative stress reduction)
- selenium (steroidogenesis, antioxidant support)
Genazzani et al., Gynecological Endocrinology 2018
Palomba et al., Human Reproduction Update 2021
Clinical Interpretation (Balanced, Not Hype)
At present, L-Leucine should be viewed as a metabolic adjuvant—not a standalone solution.
Its potential role appears strongest in:
- DOR / POSEIDON low-prognosis patients
- hypo-responsive granulosa cell environments
- aging ovaries with metabolic stress
When combined thoughtfully with agents like myo-inositol and selenium, L-Leucine may offer dual-pathway support:
mTOR activation + insulin/FSH signaling optimization
What is urgently needed:
- well-designed RCTs isolating L-Leucine
- follicular-fluid and granulosa-cell human studies
- POSEIDON-stratified outcome analysis.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
May 1, 2026, 03:13International Expert Recommendations in Emerging Reproductive Science – ESHRE
-
Apr 30, 2026, 18:45AI in Ultrasound Follicular Monitoring Moves Toward Clinical Decision Support – RBMO
-
Apr 30, 2026, 11:42ASRM Encourages Registration for Conference on Practice Growth and Innovation
-
Apr 30, 2026, 11:26ESHRE and ALPHA Launch Global Survey to Update ART Laboratory KPIs
-
Apr 30, 2026, 11:10Susanne Johnson: Advanced Gynaecology Ultrasound Course Day 2
-
Apr 30, 2026, 11:02Platelets Reduce Oxidative Stress Damage in Human Endometrial Stromal Cells in Vitro – RBMO
-
Apr 30, 2026, 10:57GREEG Day 2026: Elevate Your Ultrasound Expertise – GREEG
-
Apr 30, 2026, 10:49Up to Two-Thirds of Elite Female Athletes Experience Irregular Periods – Fertility Plus
-
Apr 30, 2026, 10:47Applications for the ESHRE5 Young Ambassadors 2026 are Still OPEN, But Not for Long! – ESHRE